CordenPharma Colorado Receives Potent Compound Safety Certification Approval from SafeBridge®

Jan 27, 2014
CordenPharma Colorado (CPC), an Active Pharmaceutical Ingredient (API) manufacturing facility in Boulder, Colorado, announces receipt of approval for the "Potent Compound Safety Certification" by SafeBridge® Consultants, Inc. (SafeBridge), headquartered in Mountain View, California. By meeting the criteria established under the SafeBridge program, CordenPharma Colorado is deemed competent and proficient in the safe handling of potent APIs and compounds of unknown toxicity and potency. The SafeBridge Potent Compound Safety Certification of CordenPharma Colorado applies to specific laboratory and manufacturing areas involved in the manufacture of APIs and synthetic intermediates.

CordenPharma Colorado maintains a robust program for safely handling highly potent APIs and has consistently demonstrated the ability to effectively contain this category of products. CPC’s core competency was developed through a wide variety of physical engineering controls - designed by experienced engineers - combined with an Industrial Hygiene program which demonstrates the effectiveness of those controls. In addition, reliable operators have been trained to make sure proper utilization and maintenance procedures are followed.

The CordenPharma Colorado API facility is now one of only ten companies, and twelve facilities worldwide, which are currently certified in the SafeBridge Potent Compound Safety program.

Read the full press release here.